Skip to main content
VRTX logo

VRTX · Vertex Pharmaceuticals Inc / Ma · Financials

Track VRTX — free
$503.25 -2.39 (-0.47%) At close · Oct 8
Market Cap
$127.55B
Shares
253.46M
Volume · Oct 8 1.49M Avg daily vol (3M) 1.16M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$12B +8.9%
FY2025 Revenue FY2008–FY2025
Net Income
$3.95B +838.1%
FY2025 Net Income FY2008–FY2025
Gross Margin
86.24% +0.1pp
FY2025 Gross Margin FY2010–FY2025
Operating Margin
34.77% +36.9pp
FY2025 Operating Margin FY2008–FY2025
Diluted EPS
$15.32 +836.5%
FY2025 Diluted EPS FY2008–FY2025
Operating Cash Flow
$3.63B +837.2%
FY2025 Operating Cash Flow FY2008–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010 FY2009 FY2008 FY2003
$13.1B – $13.2B $12.59B $12B $11.02BG $9.87B $8.93BG $7.57BG $6.21BG $4.16B $3.05B $2.49B $1.7B $1.03B $580.42M $1.21B $1.53B $1.41B $143.37M $101.89M $175.5M —
— -$43.1M — — -$44.1M -$54.8M -$61.5M -$58.2M -$58.5M — — — — — — — — — — — —
— $1.76B $1.65B $1.53B $1.26B $1.08B $904.2M $736.3M $547.8M $409.54M $275.12M $210.46M $117.15M $39.73M $88.98M $236.74M $63.63M $0 — — —
— $10.82B $10.35B $9.49B $8.61B $7.85B $6.67B $5.47B $3.62B $2.64B $2.21B $1.49B $915.19M $540.69M $1.12B $1.29B $1.35B $143.37M — — —
— — 86.24% 86.11% 87.21% 87.9% 88.06% 88.14% 86.84% 86.56% 88.95% 87.64% 88.65% 93.16% 92.66% 84.5% 95.49% 100% — — —
— $3.91B $3.91B $3.63B $3.16B $2.54B $3.05B $1.83B $1.75B $1.42B $1.32B $1.05B $995.92M $855.51M $882.1M $765.91M $707.71M $637.42M $550.27M $516.91M —
— $2.01B $1.75B $1.46B $1.14B $944.7M $840.1M $770.5M $658.5M $557.62M $496.08M $432.83M $376.58M $305.41M $356.19M $432.68M $400.72M $187.8M $130.19M $101.29M —
— — $20.2M $20.2M $1.7M — — — — — — — — — — — — — — — —
— $222.1M $209.8M $207.2M $181.3M $148.3M $125.6M $109.5M $106.9M $72.42M $61.4M $61.4M $62.34M $63.26M $48.37M $38.19M $35.04M $30.46M $30.11M $32.2M —
— — — — — — — $0 $0 -$184K $14.25M $1.26M $2.21M $50.93M $40.52M $1.84M $2.07M $1.5M $6.24M $4.32M $91.82M
— $7.81B $7.83B $11.25B $6.04B $4.62B $4.79B $3.35B $2.97B $2.41B $2.37B $1.69B $1.5B $1.27B $1.82B $1.48B $1.3B $839.45M $715.9M $638.21M —
— $4.78B $4.17B -$232.9M $3.83B $4.31B $2.78B $2.86B $1.2B $635.15M $123.24M $9.94M -$466.88M -$692.41M -$610.01M $46.73M $113.82M -$696.08M -$614.01M -$462.71M —
— — 34.77% -2.11% 38.83% 48.23% 36.73% 46.03% 28.77% 20.84% 4.95% 0.58% -45.23% -119.3% -50.33% 3.06% 8.07% -485.51% -602.63% -263.65% —
— $5B $4.38B -$25.7M $4.01B $4.46B $2.91B $2.97B $1.3B $707.57M $184.64M $71.33M -$404.54M -$629.16M -$561.64M $84.92M $148.86M -$665.62M -$583.91M -$430.51M —
— — $13.3M $30.6M $44.1M $54.8M — $58.15M $58.5M $72.47M $69.3M — — — — $16.65M $38.45M $19.28M $13.19M $13.47M —
— — — — — — — — — — — — — — — $1.94M $1.88M $1.96M $5.01M $16.33M —
— $21M -$7.7M -$86.1M -$22.8M -$164.8M $4.9M $296.6M $192.2M -$790K -$81.38M $4.13M -$6.72M $30.4M $6.89M $309K -$15.69M — — — —
— $5.27B $4.64B $248.5M $4.38B $4.23B $2.73B $3.12B $1.39B $600.24M -$15.69M -$67.37M -$557.8M -$734.88M -$626.04M $32M $60.45M -$754.63M -$642.18M -$459.85M —
— $869.3M $690M $784.1M $760.2M $910.4M $388.3M $405.2M $218.1M -$1.49B -$107.32M $16.67M $30.38M $6.96M -$122.42M -$275K $19.27M $0 — — —
— $4.41B $3.95B -$535.6M $3.62B $3.32B $2.34B $2.71B $1.18B $2.1B $263.48M -$112.05M -$556.33M -$738.56M -$445.03M -$107.03M $29.57M -$754.63M -$642.18M -$459.85M —
— — 32.94% -4.86% 36.68% 37.2% 30.92% 43.7% 28.27% 68.8% 10.59% -6.58% -53.89% -127.25% -36.72% -7.01% 2.1% -526.35% -630.27% -262.02% —
— — — — — — — $0 $0 -$9.79M -$171.85M $28.02M -$31.85M — -$242.52M $55.9M $11.61M $0 — — —
— — — — — — — $2.71B $1.18B $2.1B $263.19M -$112.05M -$556.33M -$737.64M -$503.62M $31.95M $29.28M -$754.63M -$642.18M — —
— $4.55B $3.81B -$393.5M $3.6B $3.31B $2.43B $2.65B $1.17B $2.13B $230.74M -$92.7M -$555.43M -$737.33M -$687.31M -$50.63M $29.59M -$755.05M — — —
USD/shares — $17.32 $15.46 -$2.08 $14.05 $12.97 $9.09 $10.44 $4.58 $8.24 $1.06 -$0.46 -$2.31 -$3.14 -$1.98 -$0.50 $0.14 -$3.77 -$3.71 -$3.27 —
USD/shares — $17.17 $15.32 -$2.08 $13.89 $12.82 $9.01 $10.29 $4.51 $8.09 $1.04 -$0.46 -$2.31 -$3.14 -$1.98 -$0.50 $0.14 -$3.77 -$3.71 -$3.27 —
shares — — 255.7M 257.9M 257.7M 256.1M 257.7M 259.8M 256.7M 254.29M 248.86M 244.69M 241.31M 235.31M 224.91M 211.95M 204.89M 200.4M 173.26M 140.56M —
shares — — 258M 257.9M 260.5M 259.1M 259.9M 263.4M 260.7M 259.19M 253.23M 244.69M 241.31M 235.31M 224.91M 215.26M 208.81M 200.4M 173.26M 140.56M —
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2016–FY2025: $6.12B in buybacks.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Noncurrent operating lease liabilities 2026-06-30 USD 1,977,600,000 10-Q filed 2026-08-04
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

Bridge Financing

TermLoan · Vertex Pharmaceuticals Incorporated

Reference: Bridge Financing

Active
Original principal
USD 4,500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Reported commitment: USD 4,500,000,000 Reported 2026-07-07 Disclosed facility capacity; the amount drawn and capacity available today are not established.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-07-06 Original principal USD 4,500,000,000 Commitment USD 4,500,000,000 Exact source document Parent 8-K filing · 2026-07-07
    Parent expects to finance the Merger with a combination of cash on hand and new debt financing. In connection with, and concurrently with entry into, the Merger Agreement, Parent entered into a debt commitment letter dated July 6, 2026 (the "Debt Commitment Letter") with Bank of America, N.A., BofA Securities, Inc. and Morgan Stanley Senior Funding, Inc. (collectively, the "Banks") pursuant to which the Banks have agreed to provide Parent with an unsecured 364-day bridge loan facility (the "Bridge Financing") in an aggregate principal amount of $4.5 billion on the terms and subject to the conditions set forth in the Debt Commitment Letter for the purposes of financing the transactions contemplated by the Merger Agreement.
    Issuer evidence: On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement"). Subject to the terms of the Merger Agreement, Merger Sub will be merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings set forth in the Merger Agreement.
    Supporting evidence: Parent expects to finance the Merger with a combination of cash on hand and new debt financing. In connection with, and concurrently with entry into, the Merger Agreement, Parent entered into a debt commitment letter dated July 6, 2026 (the "Debt Commitment Letter") with Bank of America, N.A., BofA Securities, Inc. and Morgan Stanley Senior Funding, Inc. (collectively, the "Banks") pursuant to which the Banks have agreed to provide Parent with an unsecured 364-day bridge loan facility (the "Bridge Financing") in an aggregate principal amount of $4.5 billion on the terms and subject to the conditions set forth in the Debt Commitment Letter for the purposes of financing the transactions contemplated by the Merger Agreement.
    Supporting evidence: Parent expects to finance the Merger with a combination of cash on hand and new debt financing. In connection with, and concurrently with entry into, the Merger Agreement, Parent entered into a debt commitment letter dated July 6, 2026 (the "Debt Commitment Letter") with Bank of America, N.A., BofA Securities, Inc. and Morgan Stanley Senior Funding, Inc. (collectively, the "Banks") pursuant to which the Banks have agreed to provide Parent with an unsecured 364-day bridge loan facility (the "Bridge Financing") in an aggregate principal amount of $4.5 billion on the terms and subject to the conditions set forth in the Debt Commitment Letter for the purposes of financing the transactions contemplated by the Merger Agreement.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 15.96×
EV/EBIT
—
Peer median 26.77×
P/E (TTM)
29.31×
Peer median 18.54×

Peer medians compare against the 13 similar-size Biotechnology companies (of 531 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023 FY2022
Pharmaceuticals $12,001,300,000 $11,020,100,000 $9,869,200,000 $8,930,700,000

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $7,548,600,000 $6,684,900,000 $6,040,400,000 $5,699,300,000 $5,287,300,000 $4,829,282,000 $3,062,555,000 $2,365,079,000
Europe $3,460,300,000 $3,453,900,000 $3,109,000,000 $2,705,500,000 $1,972,900,000 $1,126,460,000 $885,762,000 $543,179,000
Other Countries Outside of the United States and Europe $992,400,000 $881,300,000 $719,800,000 $525,900,000 $313,200,000 $249,941,000 $214,504,000 $139,339,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
TRIKAFTAKAFTRIO $10,312,700,000 $10,238,600,000 $8,944,700,000 $7,686,800,000 $5,697,200,000 $3,863,800,000 $420,100,000 $0
ALYFTREK $837,800,000 $0 $0 — — — — —
Manufactured Product Other $820,100,000 $781,500,000 $924,500,000 $1,243,900,000 — — — —
CASGEVY $115,800,000 $10,000,000 — — — — — —
JOURNAVX $59,600,000 — — — — — — —
Collaborativeand Royalty $30,700,000 $0 $0 — $1,000,000 $2,900,000 $2,100,000 $9,272,000
Kalydeco — — $475,500,000 — $684,200,000 $802,900,000 $991,000,000 $1,007,502,000
ORKAMBI — — $326,000,000 — $771,600,000 $907,500,000 $1,331,900,000 $1,262,166,000
SYMDEKO/SYMKEVI — — $123,000,000 — $420,400,000 $628,600,000 $1,417,700,000 $768,657,000
TRIKAFTA — — — — — — $420,105,000 $0
Key facts CIK 875320 CUSIP 92532F100 13F (30d) 83 filings 63 filers Visit website Investor relations